Alimta

Updated: New York: Oct 20 11:00London: Oct 20 16:00Tokyo: Oct 21 00:00 US AUBZFPGRHKIMJPLNSMIND : Regions Top Worldwide Regions Asia Australia & New Zealand Canada Europe Germany Japan Latin America U.K.

U.S.

Markets Economy/Politics Commentary Sports Culture RESOURCES: Bloomberg TV Bloomberg Radio Markets U.S.

E-Mail This Story Printer-Friendly Format Pfizer's Earnings Plunge 52 Percent on Lower Sales of Celebrex Painkiller U.S.

Stocks Fail to Build on Rally; Pfizer Drops on Forecast, SBC Gains Ford Motor Reports First Quarterly Loss Since 2003 on Declining SUV Sales Lilly's 3rd-Qtr Profit Rises 5.2% on New Drugs (Update3) Oct.

20 (Bloomberg) - Eli Lilly & Co., maker of Zyprexa, the world's top-selling schizophrenia drug, said third-quarter profit rose 5.2 percent as the company cut costs and sales of some of its newer drugs increased.

Net income for Lilly rose to $794.4 million, or 73 cents a share, from $755 million, or 69 cents, a year earlier, Indianapolis-based Lilly said in a statement.

Sales rose 10 percent to $3.6 billion, while Lilly's cost to produce these medicines rose 4 percent to $845.7 million.

Higher sales of two drugs approved in the last 20 months helped offset a 10 percent U.S.

sales decline for Zyprexa.

The Cymbalta antidepressant had a six-fold rise to $182.8 million and sales of the Since doctors have become more aware of Z...

Read more...